A synthesised four-amino-acid peptide (Lys-Glu-Asp-Ala) from Vladimir Khavinson’s bioregulator programme, directed at liver tissue and studied for effects on chromatin structure and gene accessibility.

What does chromatin decondensation mean?

DNA is wound tightly around spool-like proteins so that around two metres of it fits inside a single cell. Tightly wound DNA cannot be read. Decondensation means loosening that packing so a region becomes accessible — which is what has to happen before a gene can be used.

How is Livagen related to Vilon?

They are close structural relatives, sharing their first two amino acids. Vilon is the dipeptide Lys-Glu; Livagen extends that with two further residues to Lys-Glu-Asp-Ala. The programme built outward from short sequences, adding residues to change which tissue a peptide targets.

Is the evidence for Livagen strong?

No. The chromatin findings are mechanistically specific and interesting, but the published record is small, largely from the originating institute, and mostly at the cell level. It holds no regulatory approval anywhere.

Research Library›Bioregulators & Neuropeptides›Livagen

Liver Bioregulator

Livagen: The Liver Peptide and the Question of Unpacking DNA

A four-amino-acid sequence aimed at liver tissue, and one of the more mechanistically interesting members of the family — because the research on it goes straight at how tightly DNA is packed.

6 min read·4 studies cited·Updated July 2026

Evidence level

Preclinical only — animal and cell studies

What this level means

Quick Reference

Sequence	Lys-Glu-Asp-Ala (KEDA)
Length	Four amino acids
Target tissue	Liver
Studied for	Chromatin structure, gene accessibility
Generation	Synthetic (second-generation)

What Is Livagen?

Livagen is a synthesised tetrapeptide — Lys-Glu-Asp-Ala, sometimes written KEDA — developed within the Khavinson bioregulator programme and directed at liver tissue. The name follows the family’s usual logic: Liv-agen, from liver.

It is a close structural relative of Vilon, sharing the same opening two amino acids with two more added. That relationship is deliberate: the programme built outward from short sequences, adding residues to shift which tissue a peptide was aimed at.

The Interesting Part: Unpacking DNA

Livagen is one of the compounds where the proposed mechanism has been examined most directly, and the work concerns something called chromatin — how DNA is physically packed inside a cell.

Chromatin, in plain language: two metres of DNA has to fit inside a cell you cannot see. The way it manages this is by winding tightly around spool-like proteins, rather like a very long cable wound onto reels and stacked in a cupboard. The catch is that tightly wound cable cannot be read. For a gene to be used, that section has to be unwound and made accessible. Genes are not simply on or off — they are reachable or buried.

Published work reports that Livagen is associated with chromatin decondensation in differentiated cells — loosening the packing so that regions of DNA become accessible again — and with changes in DNA methylation, one of the chemical marks that governs whether a gene is read.

This matters because it is the kind of finding the bioregulator proposal actually requires. If these peptides influence which genes a tissue is reading, something must change about DNA accessibility. Chromatin decondensation is a specific, testable version of that claim rather than a vague one.

The Evidence, Honestly

The published record for Livagen is small, and largely confined to the research programme that developed it.

The chromatin work is genuinely interesting and mechanistically specific, which is more than can be said for much of this field. But it is cell-level laboratory work, it has not been widely replicated by independent groups, and it does not by itself establish what the compound does in a living organism. There is no regulatory approval in any jurisdiction.

The fair summary: a coherent proposed mechanism with some direct laboratory support behind it, and a long way short of established. That is a more honest position than either the enthusiasm or the dismissal this family usually attracts.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Khavinson VK, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Karger AG, Basel, 2005. Source
Fedoreyeva LI, Kireev II, Khavinson VKh, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry. Biokhimiia, 2011. PubMed
Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed